{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(10)"],"submitter":["Jamali F"],"pubmed_abstract":["<h4>Background</h4>Parkinson disease (PD) is a neurodegenerative disorder associated with a broad spectrum of motor and nonmotor symptoms. Any proposed cure needs to address the many aspects of the disease. Stem cell therapy may have potential in this regard as indicated in recent preclinical and clinical studies.<h4>Objective</h4>This protocol aims to examine the safety and therapeutic benefit of human Wharton jelly-derived mesenchymal stem cells (WJ-MScs) and their derivatives, neuronal stem cells (NSCs) in PD.<h4>Methods</h4>This clinical trial is a double-arm, single-blinded, phase I-II interventional study. Participants have been allocated to 1 of 2 groups: one receiving allogeneic WJ-MSCs alone, the other receiving NSCs and WJ-MScs. Participants are being followed-up and assessed ove"],"journal":["JMIR research protocols"],"pagination":["e29695"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8571682"],"repository":["biostudies-literature"],"pubmed_title":["A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study."],"pmcid":["PMC8571682"],"pubmed_authors":["Jamali F","Aldughmi M","Awidi A","Salameh AA","Dahbour S","Khasawneh MW"],"additional_accession":[]},"is_claimable":false,"name":"A New Tool for Safety Evaluation and a Combination of Measures for Efficacy Assessment of Cotransplanting Human Allogenic Neuronal Stem Cells and Mesenchymal Stem Cells for the Treatment of Parkinson Disease: Protocol for an Interventional Study.","description":"<h4>Background</h4>Parkinson disease (PD) is a neurodegenerative disorder associated with a broad spectrum of motor and nonmotor symptoms. Any proposed cure needs to address the many aspects of the disease. Stem cell therapy may have potential in this regard as indicated in recent preclinical and clinical studies.<h4>Objective</h4>This protocol aims to examine the safety and therapeutic benefit of human Wharton jelly-derived mesenchymal stem cells (WJ-MScs) and their derivatives, neuronal stem cells (NSCs) in PD.<h4>Methods</h4>This clinical trial is a double-arm, single-blinded, phase I-II interventional study. Participants have been allocated to 1 of 2 groups: one receiving allogeneic WJ-MSCs alone, the other receiving NSCs and WJ-MScs. Participants are being followed-up and assessed ove","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-05-29T18:53:31.072Z","creation":"2025-05-29T18:53:31.072Z"},"accession":"S-EPMC8571682","cross_references":{"pubmed":["34677138"],"doi":["10.2196/29695"]}}